Famciclovir
Brand Names: Famvir
Methodology & AI Transparency ⓘ
Famciclovir Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Famciclovir tablets, a prodrug of penciclovir, are a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) Human Immunodeficiency Virus (HIV) -Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use The efficacy and safety of famciclovir tablets have not been established for: Patients with first episode of genital herpes Patients with.
- 2 Real-world patient consensus: Real-world cohort score of 93% across 10 de-identified Famciclovir entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $10.46 mail/discount cash up to $34.50 uninsured retail (federal NADAC $0.2120).
- 4 Top reported side effects / signs: Most commonly reported Famciclovir tolerability events: nausea (12.1%), headache (10.7%), dizziness (6.6%).
Ask our AI Specialists anything about Famciclovir
Famciclovir Mechanism, CYP450 Pathways & DailyMed Monograph
Famciclovir tablets, a prodrug of penciclovir, are a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) Human Immunodeficiency Virus (HIV) -Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use The efficacy and safety of famciclovir tablets have not been established for: Patients with first episode of genital herpes Patients with.
12.1 Mechanism of Action Famciclovir is an orally administered prodrug of the anti-alpha herpes viral agent penciclovir . Famciclovir operates pharmacologically within the Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor class (RxNorm 198382; NDC 42291-414, 42291-415), engaging target pathways across 500 mg/1 Tablet, Film Coated; 125 mg/1 Tablet, Film Coated dosing.
With Mean elimination half-life of 7 to 12 hours across adult Famciclovir dosing residence kinetics and Oral fraction absorbed ranges from 64% to 76% (Famciclovir 500) bioavailability, Famciclovir undergoes dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of famciclovir and establishes therapeutic activity over oral tmax achieved within 2 to 3 hours following famciclovir ingestion.
Standard adult regimens span 500 mg/1 Tablet, Film Coated, 125 mg/1 Tablet, Film Coated, 250 mg/1 Tablet, Film Coated, 125mg Tablet, 250mg Tablet. Prescribers screen specifically against famciclovir is contraindicated in patients with known hypersensitivity to the product, its components, or denavir ® (penciclovir cream).; known hypersensitivity to the product, its components, or denavir ® (penciclovir cream)., while community micro-logs most frequently note nausea (12.1% of reports), headache (10.7% of reports), dizziness (6.6% of reports).
Transporter-mediated clearance of P-gp substrates may slow during concurrent Famciclovir administration.
Verify medication reconciliation lists so Famciclovir is not inadvertently duplicated with another herpes simplex virus nucleoside analog dna polymerase inhibitor.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Famciclovir is contraindicated in patients with known hypersensitivity to the product, its components, or Denavir ® (penciclovir cream).
- Known hypersensitivity to the product, its components, or Denavir ® (penciclovir cream).
Logged Side-Effect Incidence (10 Reports)
Famciclovir Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Famciclovir)
Human clinical trial evidence for Famciclovir is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Famciclovir Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2120/unit (~$6.36/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $10.46 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $12.03 / mo | View logs ↓ |
Famciclovir Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Famciclovir RxNorm Concept ID | 198382 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2120 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $10.46 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 93.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Famciclovir Patient Community, Cohort Filters & Dosage Logs
Cross-verified Famciclovir (herpes simplex virus nucleoside analog dna polymerase inhibitor) monograph synthesizing RxNorm 198382, openFDA FAERS signals, and $10.46–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Famciclovir community threads and patient logs by age, biological sex, dosage, and treatment duration.